For patients with metabolic syndrome, non-alcoholic fatty liver disease, or insulin resistance where visceral fat is the primary cardiovascular and metabolic driver, this mechanism distinction is clinically meaningful
Normal G-stimulation of TLR2 is beneficial to the enhancement of esophageal barrier function, but activation of the NF-B pathway through other pathways leads to esophageal barrier dysfunction when the microbiome is dysbiotic
42,47,49,50 Treatment Considerations for the Patient Taking a GLP-1 RA Given the multifaceted role of AT in tissue homeostasis, a comprehensive regenerative approach should be considered for patients experiencing GLP-1 RA-MWL, rather than an approach focused on volumetric correction
Both medications harness GLP1 pathways to curb appetite and improve metabolic health, but key differences in dosing, sideeffect profiles, and efficacy mean one may suit your lifestyle better